{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T08:04:12Z","timestamp":1722931452474},"reference-count":29,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            This study examined the association of host genetic variants with the antibody response to the quadrivalent meningococcal conjugate vaccine (MCV4) in HIV-infected youth. Genetic variants associated with severity of meningococcal disease, including the IgG Fc receptor (FC\u03b3RII)-A484T, interleukin-10 (IL-10)-A1082G, -C819T, and -C627A, IL-4-C589T, mannose binding lectin-2 (MBL2)-A\/O, -H\/L, -P\/Q, and -X\/Y, toll-like receptor 2 (TLR2)-G2408A, TLR4-A12874G and -C13174T, and TLR9-T1237C and -T1486C were determined by real-time PCR (RT-PCR) for 271 HIV-infected subjects (median, 17 years). Response was defined as a \u22654-fold increase from entry in bactericidal antibody titers to each serogroup. Generalized estimating equation (GEE) models were used to evaluate the association of allelic variants with the immunologic response to all serogroups within each subject with and without adjusting for CD4 percentage and HIV viral load. At week 4, but not after, subjects with TLR2-2408-G\/A versus -G\/G genotypes and the TLR4-12874-A\/A genotype were more likely to achieve a \u22654-fold increase overall in the four serogroups (unadjusted\n            <jats:italic>P<\/jats:italic>\n            of 0.006 and adjusted\n            <jats:italic>P<\/jats:italic>\n            of 0.008 and unadjusted\n            <jats:italic>P<\/jats:italic>\n            of 0.008 and adjusted\n            <jats:italic>P<\/jats:italic>\n            of 0.019, respectively). At week 28, the TLR9-1237 T allele was associated with enhanced antibody response (T allele versus C\/C, unadjusted\n            <jats:italic>P<\/jats:italic>\n            of 0.014 and adjusted\n            <jats:italic>P<\/jats:italic>\n            of 0.009), which was maintained at week 72 (unadjusted and adjusted\n            <jats:italic>P<\/jats:italic>\n            of 0.008). At week 72, the Fc\u03b3RII-131Arg allotype was associated with a \u22654-fold increase in antibody titer versus those with His\/His (unadjusted\n            <jats:italic>P<\/jats:italic>\n            of 0.009; adjusted\n            <jats:italic>P<\/jats:italic>\n            of &lt;0.001). These findings suggest that for HIV-infected youth, the initial antibody response to MCV4 is associated with variants in TLR2 and TLR4 while the long-term response is associated with genetic polymorphisms in TLR9 and Fc\u03b3RIIa.\n          <\/jats:p>","DOI":"10.1128\/cvi.00042-13","type":"journal-article","created":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T02:27:39Z","timestamp":1366252059000},"page":"900-906","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["Genetic Variants in Toll-Like Receptor 2 (TLR2), TLR4, TLR9, and FC\u03b3 Receptor II Are Associated with Antibody Response to Quadrivalent Meningococcal Conjugate Vaccine in HIV-Infected Youth"],"prefix":"10.1128","volume":"20","author":[{"given":"Stephen A.","family":"Spector","sequence":"first","affiliation":[{"name":"University of California, San Diego, La Jolla, California, USA"},{"name":"Rady Children's Hospital, San Diego, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Qin","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Lujan-Zilbermann","sequence":"additional","affiliation":[{"name":"University of South Florida, Morsani College of Medicine, Tampa, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumud K.","family":"Singh","sequence":"additional","affiliation":[{"name":"University of California, San Diego, La Jolla, California, USA"},{"name":"Rady Children's Hospital, San Diego, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith G.","family":"Warshaw","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paige L.","family":"Williams","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Jean-Philippe","sequence":"additional","affiliation":[{"name":"Henry Jackson Foundation for the Advancement of Military Medicine, National Institute of Allergy and Infectious Diseases, Division of AIDS, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence","family":"Fenton","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George K.","family":"Siberry","sequence":"additional","affiliation":[{"name":"Pediatric, Adolescent, and Maternal AIDS Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the IMPAACT P1065 Protocol Team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1651-2227.2008.01163.x","article-title":"A toll-like receptor 4 variant is associated with fatal outcome in children with invasive meningococcal disease","volume":"98","author":"Faber J","year":"2009","unstructured":"FaberJ HenningerN FinnA ZenzW ZeppF KnufM. 2009. A toll-like receptor 4 variant is associated with fatal outcome in children with invasive meningococcal disease. Acta Paediatr. 98:548\u2013552.","journal-title":"Acta Paediatr."},{"key":"e_1_3_3_3_2","first-page":"1391","article-title":"Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. 2011. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb. Mortal. Wkly. Rep. 60:1391\u20131392.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_3_4_2","first-page":"1018","article-title":"Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. 2011. Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease. MMWR Morb. Mortal. Wkly. Rep. 60:1018\u20131019.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/INF.0b013e3181c38f3b","article-title":"Phase I\/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents","volume":"29","author":"Siberry GK","year":"2010","unstructured":"SiberryGK WilliamsPL Lujan-ZilbermannJ WarshawMG SpectorSA DeckerMD HeckmanBE DemskeEF ReadJS Jean-PhilippeP KabatW NachmanS, IMPAACT P1065 Protocol Team. 2010. Phase I\/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. Pediatr. Infect. Dis. J. 29:391\u2013396.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2012.04.005","article-title":"Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus","volume":"161","author":"Lujan-Zilbermann J","year":"2012","unstructured":"Lujan-ZilbermannJ WarshawMG WilliamsPL SpectorSA DeckerMD AbzugMJ HeckmanB ManzellaA KabatB Jean-PhilippeP NachmanS SiberrySK, IMPAACT P1065 Protocol Team. 2012. Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J. Pediatr. 161:676\u2013681.","journal-title":"J. Pediatr."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.640"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70261-5"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"B90","DOI":"10.1016\/j.vaccine.2009.05.002","article-title":"Genetic polymorphisms in host response to meningococcal infection: the role of susceptibility and severity genes","volume":"27","author":"Wright V","year":"2009","unstructured":"WrightV HibberdM LevinM. 2009. Genetic polymorphisms in host response to meningococcal infection: the role of susceptibility and severity genes. Vaccine 27(Suppl 2):B90\u2013B102.","journal-title":"Vaccine"},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijmm.2008.06.007","article-title":"Recognition of meningococcal molecular patterns by innate immune receptors","volume":"299","author":"Schmitt C","year":"2009","unstructured":"SchmittC VillwockA KurzaiO. 2009. Recognition of meningococcal molecular patterns by innate immune receptors. Int. J. Med. Microbiol. 299:9\u201320.","journal-title":"Int. J. Med. Microbiol."},{"key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"R488","DOI":"10.1016\/j.cub.2011.05.039","article-title":"Toll-like receptors","volume":"21","author":"Moresco EM","year":"2011","unstructured":"MorescoEM LaVineD BeutlerB. 2011. Toll-like receptors. Curr. Biol. 21:R488\u2013R493.","journal-title":"Curr. Biol."},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood-2008-07-019307","article-title":"TLRs and innate immunity","volume":"113","author":"Beutler BA","year":"2009","unstructured":"BeutlerBA. 2009. TLRs and innate immunity. Blood 113:1399\u20131407.","journal-title":"Blood"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJM198812153192404","article-title":"Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex","volume":"319","author":"Schmitt FA","year":"1988","unstructured":"SchmittFA BigleyJW McKinnisR LoguePE EvansRW DruckerJL. 1988. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 319:1573\u20131578.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00615-08"},{"key":"e_1_3_3_15_2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1473-3099(10)70045-1","article-title":"Host genetics and outcome in meningococcal disease: a systematic review and meta-analysis","volume":"10","author":"Brouwer MC","year":"2010","unstructured":"BrouwerMC ReadRC van de BeekD. 2010. Host genetics and outcome in meningococcal disease: a systematic review and meta-analysis. Lancet Infect. Dis. 10:262\u2013274.","journal-title":"Lancet Infect. Dis."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.159.10.907"},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection","volume":"69","author":"Borrow R","year":"2001","unstructured":"BorrowR AndrewsN GoldblattD MillerE. 2001. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect. Immun. 69:1568\u20131573.","journal-title":"Infect. Immun."},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1006\/biol.2000.0253","article-title":"Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines","volume":"28","author":"Jodar L","year":"2000","unstructured":"JodarL CartwrightK FeaversIM. 2000. Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines. Biologicals 28:193\u2013197.","journal-title":"Biologicals"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05379-11"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015692"},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.it.2005.11.005","article-title":"Triggering TLR signaling in vaccination","volume":"27","author":"van Duin D","year":"2006","unstructured":"van DuinD MedzhitovR ShawAC. 2006. Triggering TLR signaling in vaccination. Trends Immunol. 27:49\u201355.","journal-title":"Trends Immunol."},{"key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ni1112","article-title":"Toll-like receptor control of the adaptive immune responses","volume":"5","author":"Iwasaki A","year":"2004","unstructured":"IwasakiA MedzhitovR. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5:987\u2013995.","journal-title":"Nat. Immunol."},{"key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1126\/science.1135299","article-title":"Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling","volume":"314","author":"Gavin AL","year":"2006","unstructured":"GavinAL HoebeK DuongB OtaT MartinC BeutlerB NemazeeD. 2006. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314:1936\u20131938.","journal-title":"Science"},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.it.2009.03.008","article-title":"New insights into the regulation of human B-cell differentiation","volume":"30","author":"Schmidlin H","year":"2009","unstructured":"SchmidlinH DiehlSA BlomB. 2009. New insights into the regulation of human B-cell differentiation. Trends Immunol. 30:277\u2013285.","journal-title":"Trends Immunol."},{"key":"e_1_3_3_25_2","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1182\/blood-2006-03-008441","article-title":"CpG DNA activation and plasma-cell differentiation of CD27-naive human B cells","volume":"109","author":"Huggins J","year":"2007","unstructured":"HugginsJ PellegrinT FelgarRE WeiC BrownM ZhengB MilnerEC BernsteinSH SanzI ZandMS. 2007. CpG DNA activation and plasma-cell differentiation of CD27-naive human B cells. Blood 109:1611\u20131619.","journal-title":"Blood"},{"key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"800","DOI":"10.4049\/jimmunol.180.2.800","article-title":"CpG drives human transitional B cells to terminal differentiation and production of natural antibodies","volume":"180","author":"Capolunghi F","year":"2008","unstructured":"CapolunghiF CascioliS GiordaE RosadoMM PlebaniA AuritiC SegantiG ZuntiniR FerrariS CagliusoM QuintiI CarsettiR. 2008. CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J. Immunol. 180:800\u2013808.","journal-title":"J. Immunol."},{"key":"e_1_3_3_27_2","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1126\/science.1076071","article-title":"Maintenance of serological memory by polyclonal activation of human memory B cells","volume":"298","author":"Bernasconi NL","year":"2002","unstructured":"BernasconiNL TraggiaiE LanzavecchiaA. 2002. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298:2199\u20132202.","journal-title":"Science"},{"key":"e_1_3_3_28_2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.coi.2010.10.003","article-title":"Genetic variation, Fc\u03b3 receptors, KIRs and infection: the evolution of autoimmunity","volume":"22","author":"Espeli M","year":"2010","unstructured":"EspeliM NiedererHA TraherneJA TrowsdaleJ SmithKG. 2010. Genetic variation, Fc\u03b3 receptors, KIRs and infection: the evolution of autoimmunity. Curr. Opin. Immunol. 22:715\u2013722.","journal-title":"Curr. Opin. Immunol."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.13.4.507-510.2006"},{"key":"e_1_3_3_30_2","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1086\/514935","article-title":"Association of human Fc\u03b3RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease","volume":"27","author":"Platonov AE","year":"1998","unstructured":"PlatonovAE ShipulinGA VershininaIV DankertJ van de WinkelJG KuijperEJ. 1998. Association of human Fc\u03b3RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease. Clin. Infect. Dis. 27:746\u2013750.","journal-title":"Clin. Infect. Dis."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00042-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00042-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:49:27Z","timestamp":1627591767000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00042-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1128\/CVI.00042-13"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00042-13","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"type":"print","value":"1556-6811"},{"type":"electronic","value":"1556-679X"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"2013-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-04-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-05-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}